4//SEC Filing
KRAUSE BRIAN R 4
Accession 0001209191-04-008012
CIK 0001066745other
Filed
Feb 8, 7:00 PM ET
Accepted
Feb 9, 9:25 PM ET
Size
9.9 KB
Accession
0001209191-04-008012
Insider Transaction Report
Form 4
KRAUSE BRIAN R
VP Preclinical Res.& Discovery
Transactions
- Exercise/Conversion
Common Stock
2004-02-05+60,821→ 62,436 total - Disposition from Tender
Common Stock
2004-02-05$35.00/sh−62,436$2,185,260→ 0 total - Exercise/Conversion
Stock Option (right to buy)
2004-02-05−60,821→ 129,179 total→ Common Stock (60,821 underlying)
Footnotes (6)
- [F1]The price for the acquisition of these shares range from $4.19 per share to $6.26 per share.
- [F2]Includes allocation of 262 shares of Esperion Therapeutics, Inc. Common Stock under Esperion Therapeutics, Inc. 401(k) Savings Plan. Indirect beneficial ownership of 500 shares as custodian for son and 500 shares as custodian for daughter.
- [F3]Disposed of pursuant to an Agreement and Plan of Merger, dated December 19, 2003 and as amended on January 16, 2004, by and among Esperion Therapeutics, Inc., Enzo Aquisition Corp., and Pfizer Inc., in exchange for a cash payment representing the tender offer price of $35.00 per common share.
- [F4]The options vest in sixteen cumulative quarterly installments beginning on the end of each three month period from the date of grant.
- [F5]The expiration dates of these options range from March 13, 2011 to January 14, 2012.
- [F6]Per SEC Rules for this transaction, this field is not required.
Documents
Issuer
ESPERION THERAPEUTICS INC/MI
CIK 0001066745
Entity typeother
Related Parties
1- filerCIK 0001242614
Filing Metadata
- Form type
- 4
- Filed
- Feb 8, 7:00 PM ET
- Accepted
- Feb 9, 9:25 PM ET
- Size
- 9.9 KB